Launxp Biomedical Co (ROCO:6876) EBITDA Margin %: 0.00% (As of Dec. 2025)


ROCO:6876 Launxp Biomedical Co Ltd ROCO:6876
11 GF Score
Price NT$15.90
! 4 Warning Signs
View Full Analysis

What is Launxp Biomedical Co EBITDA Margin %?

Launxp Biomedical Co ROCO:6876 -0.93% 11 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates ROCO:6876 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 943 Biotechnology companies, Launxp Biomedical Co ranks worse than 106044.43% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Launxp Biomedical Co's EBITDA for the six months ended in Dec. 2025 was NT$-54.72 Mil. Launxp Biomedical Co's Revenue for the six months ended in Dec. 2025 was NT$0.00 Mil. Therefore, Launxp Biomedical Co's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Launxp Biomedical Co  (ROCO:6876) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Launxp Biomedical Co EBITDA Margin % Related Terms

Launxp Biomedical Co EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Launxp Biomedical Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Launxp Biomedical Co EBITDA Margin % Chart

Launxp Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 -712,436.36 -3,206.44 0.00

Launxp Biomedical Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -462,027.27 -1,475.72 0.00 0.00 0.00

ROCO:6876 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Launxp Biomedical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Launxp Biomedical Co EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Launxp Biomedical Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Launxp Biomedical Co's EBITDA Margin % falls into.


ROCO:6876
11GF Score
Launxp Biomedical Co Ltd ROCO:6876
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Launxp Biomedical Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Launxp Biomedical Co's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-106.889/0
= %

Launxp Biomedical Co's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-54.72/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Launxp Biomedical Co (ROCO:6876) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Launxp Biomedical Co and its competitors. According to the industry distribution chart, Launxp Biomedical Co ranks #999999 out of 943 companies in the Biotechnology industry.
Is Launxp Biomedical Co's EBITDA Margin % too high?
Launxp Biomedical Co's current EBITDA Margin % is 0.00%. Based on the distribution chart, Launxp Biomedical Co ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Launxp Biomedical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Launxp Biomedical Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Launxp Biomedical Co ranks #999999 out of 943 companies for EBITDA Margin %. This places Launxp Biomedical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Launxp Biomedical Co and its competitors. Launxp Biomedical Co's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Launxp Biomedical Co stock overvalued right now?
Launxp Biomedical Co (ROCO:6876) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Launxp Biomedical Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Launxp Biomedical Co (ROCO:6876), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Launxp Biomedical Co Business Description

Address 10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.
11GF Score

Get the complete analysis for ROCO:6876

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.90
Price